Dogwood Therapeutics, trading under the ticker DWTX, has successfully met the financial criteria needed to maintain its listing on Nasdaq, specifically resolving a previous shortfall in stockholders' equity. The compliance was officially confirmed in writing by Nasdaq, following a period in which the company fell below the necessary equity threshold.
Initially, on November 15, 2024, Dogwood was alerted to its failure to meet Nasdaq’s Listing Rule 5550(b)(1), which mandates a minimum stockholders’ equity of $2.5 million. In response, the company proposed a detailed plan on December 27, 2024, to restore compliance and sustain the required equity levels.
Nasdaq provided Dogwood with a timeline to rectify the situation, allowing until May 14, 2025, to meet the minimum requirement. Subsequently, Dogwood's efforts proved successful, as documented in a Form 8-K filed on April 3, 2025. By April 8, 2025, Nasdaq confirmed that Dogwood’s stockholders' equity had been restored to the required minimum, thereby reinstating the company's compliance with the Nasdaq Listing Rule 5550(b)(1).
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Dogwood Therapeutics Inc (DWTX, Financial) is $3.00 with a high estimate of $5.00 and a low estimate of $1.00. The average target implies an upside of 2.04% from the current price of $2.94. More detailed estimate data can be found on the Dogwood Therapeutics Inc (DWTX) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Dogwood Therapeutics Inc's (DWTX, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
